Glaukos Corporation, Allergan, and Ivantis, Inc. are Dominating the Europe Micro Invasive Glaucoma Surgical (MIGS) Devices Market in 2019

Europe Micro Invasive Glaucoma Surgical (MIGS) Devices Market is expected to grow with the CAGR of 32.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-micro-invasive-glaucoma-surgery-migs-devices-market

Europe micro invasive glaucoma surgical (MIGS) devices market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in with launching new services and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced service portfolio.

For instance,

  • In November 2019, Glaukos Corporation announced the acquisition of Avedro, Inc., which also works in the development of products for corneal health. This acquisition has led to widening of product portfolio. Also, the revenue generation of the company is more in the market.

Glaukos Corporation is the dominating player in Europe micro invasive glaucoma surgical (MIGS) devices market. The other key players existing in the market are Allergan, Ivantis, Inc., Ellex (Nova Eye Medical), Alcon, BVI, Johnson and Johnson Surgical Vision, Inc., MicroSurgical Technology, MOLTENO Ophthalmic Ltd, New World Medical, Inc., Santen Pharmaceutical Co., Ltd., and Sight Sciences among others.

Europe Micro Invasive Glaucoma Surgery (MIGS) Devices MarketGlaukos Corporation:

Glaukos Corporation headquartered in California, U.S. and founded in 1998. The company's focus is to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases. The company offers its product in several categories such as glaucoma, corneal health, and retinal disease, Glaucoma is the market focused category. The company has wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such Avedro, Inc.(U.S.), Glaukos Europe GmbH (Europe), Glaukos Canada Inc.(Canada) and SASU France Glaukos (France) among others.

 For instance,

  • In December 2019, Glaukos Corporation announced that it has completed the patient enrolment for IDE trial of iStent infinite Trabecular Micro-Bypass System. It is used as a standalone procedure and is used to reduce elevated intra ocular pressure. The product launched led to increased revenue generation for the company.

Allergan:

Allergan is headquartered in Dublin, Ireland and incorporated in 2013. The company is focused on developing, manufacturing, commercializing the branded pharmaceutical device, biologic, surgical and regenerative medicine products for patients around the world. The company offers its product in several categories central nervous system, eye care, gastroenterology, and medical aesthetics. Eye care is the market focused category. The company has wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such as ZELTIQ Aesthetics (U.S.), ALLERGAN LIMITED (U.K), Envy Medical, Inc. (U.S.), Kythera Biopharmaceuticals, Inc.(U.S.) and Actavis Group ehf. (Iceland) among others.

For instance,

  • In April 2020, Allergan announced that China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN Gel Stent for the patients suffering from refractory glaucoma. As this is the first product to get the approval in China, which will lead to increased revenue generation in the market.

Ivantis, Inc.:

Ivantis, Inc is headquartered in California, U.S. The company is focused on expanding patient treatment and improving outcomes through innovative minimally invasive glaucoma surgical (MIGS) solutions. The company offers hydrus microstent product. The company has wide presence across North America, Europe, and Asia-Pacific.

For instance,

  • In October 2019, Ivantis, Inc. announced the completion of enrollment of International SPECTRUM Registry for hydrus microstent. This completion could be provided as an insightful complement to their level 1 controlled trial publications. Hence, this product was preferred more and the revenue was also increased.